|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL10 |
Gene summary for METTL10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL10 | Gene ID | 399818 |
| Gene name | EEF1A lysine methyltransferase 2 | |
| Gene Alias | C10orf138 | |
| Cytomap | 10q26.13 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q5JPI9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 399818 | METTL10 | P1T-E | Human | Esophagus | ESCC | 1.01e-02 | 1.58e-01 | 0.0875 |
| 399818 | METTL10 | P2T-E | Human | Esophagus | ESCC | 8.18e-34 | 6.11e-01 | 0.1177 |
| 399818 | METTL10 | P4T-E | Human | Esophagus | ESCC | 3.53e-21 | 5.31e-01 | 0.1323 |
| 399818 | METTL10 | P5T-E | Human | Esophagus | ESCC | 9.90e-37 | 7.11e-01 | 0.1327 |
| 399818 | METTL10 | P8T-E | Human | Esophagus | ESCC | 9.25e-17 | 1.98e-01 | 0.0889 |
| 399818 | METTL10 | P9T-E | Human | Esophagus | ESCC | 3.42e-10 | 1.12e-01 | 0.1131 |
| 399818 | METTL10 | P10T-E | Human | Esophagus | ESCC | 5.18e-14 | 2.20e-01 | 0.116 |
| 399818 | METTL10 | P11T-E | Human | Esophagus | ESCC | 1.64e-14 | 3.57e-01 | 0.1426 |
| 399818 | METTL10 | P12T-E | Human | Esophagus | ESCC | 4.60e-17 | 4.30e-01 | 0.1122 |
| 399818 | METTL10 | P15T-E | Human | Esophagus | ESCC | 1.28e-08 | 1.90e-01 | 0.1149 |
| 399818 | METTL10 | P16T-E | Human | Esophagus | ESCC | 2.33e-26 | 5.18e-01 | 0.1153 |
| 399818 | METTL10 | P17T-E | Human | Esophagus | ESCC | 3.20e-08 | 3.18e-01 | 0.1278 |
| 399818 | METTL10 | P19T-E | Human | Esophagus | ESCC | 2.28e-05 | 4.89e-01 | 0.1662 |
| 399818 | METTL10 | P20T-E | Human | Esophagus | ESCC | 9.24e-14 | 2.02e-01 | 0.1124 |
| 399818 | METTL10 | P21T-E | Human | Esophagus | ESCC | 1.08e-18 | 3.00e-01 | 0.1617 |
| 399818 | METTL10 | P22T-E | Human | Esophagus | ESCC | 2.40e-11 | 1.50e-01 | 0.1236 |
| 399818 | METTL10 | P23T-E | Human | Esophagus | ESCC | 1.30e-20 | 4.14e-01 | 0.108 |
| 399818 | METTL10 | P24T-E | Human | Esophagus | ESCC | 1.03e-22 | 5.31e-01 | 0.1287 |
| 399818 | METTL10 | P26T-E | Human | Esophagus | ESCC | 1.15e-27 | 5.34e-01 | 0.1276 |
| 399818 | METTL10 | P27T-E | Human | Esophagus | ESCC | 1.35e-17 | 4.15e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL10 | SNV | Missense_Mutation | c.863N>T | p.Ser288Leu | p.S288L | Q5JPI9 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| METTL10 | SNV | Missense_Mutation | c.604G>C | p.Glu202Gln | p.E202Q | Q5JPI9 | protein_coding | tolerated(0.11) | benign(0.085) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD | |
| METTL10 | deletion | Frame_Shift_Del | novel | c.842delG | p.Gly281AspfsTer43 | p.G281Dfs*43 | Q5JPI9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| METTL10 | SNV | Missense_Mutation | c.458N>C | p.Lys153Thr | p.K153T | Q5JPI9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| METTL10 | SNV | Missense_Mutation | novel | c.591N>C | p.Glu197Asp | p.E197D | Q5JPI9 | protein_coding | tolerated(0.39) | benign(0.113) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| METTL10 | deletion | Frame_Shift_Del | c.769delN | p.Cys257AlafsTer67 | p.C257Afs*67 | Q5JPI9 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| METTL10 | SNV | Missense_Mutation | novel | c.71N>T | p.Glu24Val | p.E24V | Q5JPI9 | protein_coding | tolerated(0.08) | benign(0.058) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| METTL10 | SNV | Missense_Mutation | c.399N>T | p.Lys133Asn | p.K133N | Q5JPI9 | protein_coding | tolerated(0.23) | possibly_damaging(0.86) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| METTL10 | SNV | Missense_Mutation | novel | c.480N>A | p.Ser160Arg | p.S160R | Q5JPI9 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| METTL10 | SNV | Missense_Mutation | novel | c.271N>T | p.Gly91Cys | p.G91C | Q5JPI9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |